Lycopodium Limited
ASX: LYL
Lycopodium’s earnings momentum is fading as project activity slows and margin headwinds build—raising caution despite its low valuation.
(Source: TradingView) 3-Month Performance Profile of LYL compared to the S&P/ASX 200 (XJO).
Lycopodium’s H1 FY25 results reflect early signs of operational deceleration, with revenue declining 5% YoY to $165.88 million and net pro
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
